FGFR1 and neoplasm: Surufatinib, a novel small-molecule inhibitor, exhibits a unique dual action by targeting both tumor angiogenesis (VEGFR1/2/3 and FGFR1) and immune evasion through the macrophage colony-stimulating factor 1 (CSF1) receptor.